ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 66

Genome-Wide DNA Methylation Profiling of OA PBMCs Reveals Slowed Epigenetic Aging Among Rapid Radiographic Progressors: Data from the Osteoarthritis Initiative (OAI)

Alexander Rivas1, Madison Andrews2 and Matlock A. Jeffries3, 1Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3Department of Medicine, Division of Rheumatology, Immunology, and Allergy, University of Oklahoma Health Sciences Center, Oklahoma City, OK

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, Epigenetics, osteoarthritis and prognostic factors

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Biology and Pathology of Bone and Joint Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Extensive evidence has correlated epigenetic alterations in articular tissues with both the presence and progression of human osteoarthritis. A recent study demonstrated that accelerated DNA methylation aging was present in OA cartilage compared to controls but not in peripheral blood samples from a mixed population of knee, hip, and hand OA patients. To further clarify epigenetic age changes specifically in knee OA, we examined the DNA methylation aging rate in peripheral blood mononuclear cells (PBMCs) at baseline from knee OA patients with rapid radiographic progression compared to well-matched nonprogressors enrolled in the Osteoarthritis Initiative (OAI).

Methods: Peripheral blood mononuclear cell (PBMC) DNA was obtained from baseline blood draws of 64 OA patients enrolled in the Osteoarthritis Initiative (OAI) longitudinal study. 32 rapidly-progressive OA patients, defined as ≥1.0mm radiographic joint space loss or joint replacement within the first 24 months of follow-up were compared to 32 non-progressive OA patients defined as ≤0.5mm radiographic joint space loss over 48 months of follow-up. There were no differences in age, sex, race, BMI, baseline K/L grade, or calculated PBMC subset composition between rapid- and non-progressors. DNA methylation was quantified with Illumina HumanMethylation 450k arrays. Epigenetic age was estimated with the algorithm described by Horvath et. al., using 353 age-associated CpG sites. This epigenetic age was compared to chronological age to calculate epigenetic-chronological age discordance (ΔAge) and group differences compared with a Student t-test. ΔAge was correlated with individual CpG methylation sites of rapid progressors, and Pearson values calculated. Correlation was considered significant if Pearson’s r values were ≤-0.55 or ≥0.55 (p≤0.001). Pathway analysis of correlated genes was performed with the Ingenuity Pathway Analysis (IPA) system.

Results: The baseline DNA methylation aging rate in rapidly progressive (RP) knee OA patients was decelerated compared to nonprogressors (NP) and to chronological age (ΔAge-RP: -4.9±1.4 vs. ΔAge-NP: -0.071±1.3 mean±SEM years less than chronological age, p=0.015). 1165 CpG sites were correlated with ΔAge in rapid progressors, corresponding to 755 genes. Ontologic analysis of highly correlated genes showed association of the STAT3 pathway (p=6E-4), Notch signaling (p=1E-3), axonal guidance signaling (p=7E-3), CREB signaling (p=2E-2), NFAT signaling (p=2E-2), and autophagy (p=4E-2) among others. Associated upstream regulators included FGF2 (p=3E-5), SMAD4 (p=9E-4), SMAD5 (p=1E-3, TNF (p=4E-3), and TGFB1 (p=4E-3), among others.

Conclusion: Our data reveal that a decelerated peripheral blood differential DNA methylation age epigenotype is present at baseline in rapidly progressive knee OA patients, but not in nonprogressive knee OA patients. The genes correlated with this methylation age deceleration cluster in pathways previously associated with OA in articular tissues. Our data reinforce the notion that OA is a heterogeneous disease composed of distinct subgroups, and suggests that future epigenetic investigation of immune cell subsets may be beneficial in unraveling OA pathogenesis.


Disclosure: A. Rivas, None; M. Andrews, None; M. A. Jeffries, None.

To cite this abstract in AMA style:

Rivas A, Andrews M, Jeffries MA. Genome-Wide DNA Methylation Profiling of OA PBMCs Reveals Slowed Epigenetic Aging Among Rapid Radiographic Progressors: Data from the Osteoarthritis Initiative (OAI) [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/genome-wide-dna-methylation-profiling-of-oa-pbmcs-reveals-slowed-epigenetic-aging-among-rapid-radiographic-progressors-data-from-the-osteoarthritis-initiative-oai/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/genome-wide-dna-methylation-profiling-of-oa-pbmcs-reveals-slowed-epigenetic-aging-among-rapid-radiographic-progressors-data-from-the-osteoarthritis-initiative-oai/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology